Medacta Group SA

BATS-CHIXE:MOVEZ Stock Report

Market Cap: CHF 2.4b

Medacta Group Valuation

Is MOVEZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOVEZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MOVEZ (CHF122.8) is trading above our estimate of fair value (CHF78.9)

Significantly Below Fair Value: MOVEZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOVEZ?

Other financial metrics that can be useful for relative valuation.

MOVEZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.3x
Enterprise Value/EBITDA22.6x
PEG Ratio2.7x

Price to Earnings Ratio vs Peers

How does MOVEZ's PE Ratio compare to its peers?

The above table shows the PE ratio for MOVEZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.4x
SN. Smith & Nephew
41.1x21.7%UK£8.6b
NIOX NIOX Group
30.6x17.4%UK£290.9m
EKF EKF Diagnostics Holdings
55.4x35.3%UK£130.2m
CTEC ConvaTec Group
46.6x20.7%UK£4.8b
MOVEZ Medacta Group
53.4x20.0%CHF 2.4b

Price-To-Earnings vs Peers: MOVEZ is expensive based on its Price-To-Earnings Ratio (53.4x) compared to the peer average (43.4x).

Price to Earnings Ratio vs Industry

How does MOVEZ's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.3%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.3%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: MOVEZ is expensive based on its Price-To-Earnings Ratio (53.4x) compared to the European Medical Equipment industry average (30.3x).

Price to Earnings Ratio vs Fair Ratio

What is MOVEZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOVEZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio53.4x
Fair PE Ratio35.4x

Price-To-Earnings vs Fair Ratio: MOVEZ is expensive based on its Price-To-Earnings Ratio (53.4x) compared to the estimated Fair Price-To-Earnings Ratio (35.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOVEZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 122.80
CHF 139.16
+13.3%
4.3%CHF 148.77CHF 129.61n/a7
Jun ’25CHF 123.10
CHF 142.95
+16.1%
5.7%CHF 156.19CHF 131.46n/a7
May ’25CHF 111.80
CHF 142.95
+27.9%
5.7%CHF 156.19CHF 131.46n/a7
Apr ’25CHF 121.80
CHF 142.25
+16.8%
5.4%CHF 154.50CHF 130.04n/a7
Mar ’25CHF 127.80
CHF 140.59
+10.0%
7.3%CHF 156.49CHF 126.46n/a7
Feb ’25CHF 130.70
CHF 138.68
+6.1%
7.0%CHF 152.47CHF 125.02n/a7
Jan ’25CHF 126.00
CHF 133.43
+5.9%
10.8%CHF 152.89CHF 110.76n/a5
Dec ’24CHF 116.60
CHF 132.35
+13.5%
12.0%CHF 156.22CHF 113.18n/a5
Nov ’24CHF 108.60
CHF 132.35
+21.9%
12.0%CHF 156.22CHF 113.18n/a5
Oct ’24CHF 115.80
CHF 125.20
+8.1%
10.1%CHF 142.98CHF 114.01n/a3
Sep ’24CHF 123.80
CHF 128.43
+3.7%
11.8%CHF 152.39CHF 113.21n/a4
Aug ’24CHF 126.20
CHF 128.43
+1.8%
11.8%CHF 152.39CHF 113.21n/a4
Jul ’24CHF 120.60
CHF 113.93
-5.5%
15.1%CHF 142.93CHF 91.61n/a5
Jun ’24CHF 115.00
CHF 103.57
-9.9%
6.6%CHF 111.63CHF 92.70CHF 123.104
May ’24CHF 120.20
CHF 103.57
-13.8%
6.6%CHF 111.63CHF 92.70CHF 111.804
Apr ’24CHF 99.30
CHF 103.57
+4.3%
6.6%CHF 111.63CHF 92.70CHF 121.804
Mar ’24CHF 101.00
CHF 106.79
+5.7%
4.5%CHF 111.99CHF 99.33CHF 127.804
Feb ’24CHF 99.30
CHF 106.39
+7.1%
2.6%CHF 110.50CHF 102.87CHF 130.704
Jan ’24CHF 103.60
CHF 106.02
+2.3%
3.1%CHF 109.36CHF 100.91CHF 126.004
Dec ’23CHF 102.00
CHF 106.02
+3.9%
3.1%CHF 109.36CHF 100.91CHF 116.604
Nov ’23CHF 88.70
CHF 108.27
+22.1%
5.5%CHF 117.43CHF 101.14CHF 108.604
Oct ’23CHF 83.80
CHF 105.94
+26.4%
6.2%CHF 114.37CHF 98.51CHF 115.803
Sep ’23CHF 85.25
CHF 112.33
+31.8%
7.6%CHF 119.81CHF 100.32CHF 123.803
Aug ’23CHF 94.00
CHF 112.54
+19.7%
7.7%CHF 119.94CHF 100.44CHF 126.203
Jul ’23CHF 91.50
CHF 127.49
+39.3%
3.9%CHF 134.32CHF 122.97CHF 120.603
Jun ’23CHF 108.40
CHF 130.03
+20.0%
3.7%CHF 134.71CHF 123.33CHF 115.003

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.